Biofrontera AG
Biofrontera AG: Biofrontera AG to propose resolution for ordinary capital increase to the Annual General Meeting
Biofrontera AG / Key word(s): Capital Increase Ad-hoc Release pursuant to Art. 17 MAR – The Company’s share capital shall be increased by up to EUR 8,969,870 by issuing up to 8,969,870 new registered no-par value shares, each with a notional interest in the share capital of EUR 1.00 (“New Shares”), against cash contributions. – The subscription right will be granted to the shareholders indirectly based on a 5 : 1 ratio and at a subscription price to be determined. – The subscription price will be dutifully determined by a resolution of the Management Board (Vorstand) with the approval of the Supervisory Board (Aufsichtsrat), taking into account market conditions, however, it must not be lower than the minimum amount pursuant to Section 9 (1) of the German Stock Corporation Act (AktG). Further details will be published in the convocation of the Annual General Meeting, which will be published in the Federal Gazette. The proceeds from the capital increase will be used to continue financing clinical studies for the further development of Ameluz(R), for sales and marketing expenses of Ameluz(R) particularly in the US and to cover costs of the current business operations. Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen Contact: Biofrontera AG
16-Apr-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Biofrontera AG |
Hemmelrather Weg 201 | |
51377 Leverkusen | |
Germany | |
Phone: | +49 (0)214 87632 0 |
Fax: | +49 (0)214 87632 90 |
E-mail: | ir@biofrontera.com |
Internet: | www.biofrontera.com |
ISIN: | DE0006046113, NASDAQ: BFRA |
WKN: | 604611 |
Listed: | Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq |
EQS News ID: | 1023055 |
End of Announcement | DGAP News Service |